Quantcast

Industry news that matters to you.  Learn more

Large International Tumor Profiling Study of Colorectal Cancer Provides Key Treatment Insights for World’s Third Most Common Cancer

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, recently presented a large international tumor profiling study of colorectal cancer at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by Caris Molecular Intelligence™ the study represents the largest, multi-national analysis in a single laboratory setting of the main molecular anomalies in colorectal cancer. Colorectal cancer (CRC) is the third most common cancer worldwide, with metastatic disease accounting for 40 to 50 percent of newly diagnosed patients.